CV Sciences Inc logo

CVSI - CV Sciences Inc News Story

$0.15 0.0  0.0%

Last Trade - 03/12/21

Sector
Healthcare
Size
Micro Cap
Market Cap £12.5m
Enterprise Value £11.3m
Revenue £15.3m
Position in Universe 6659th / 7306

CV Sciences, Inc. Applauds the California Legislature for Passage of AB 45

Thu 7th October, 2021 6:01pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211007:nGNX3cyxNX&default-theme=true


SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI)
(the “Company”, “CV Sciences”, “our”, “us” or “we”), a
preeminent supplier and manufacturer of hemp cannabidiol (CBD) products,
applauds the California Legislature of its passage of AB 45
(https://www.globenewswire.com/Tracker?data=Q1KPZnPPbOYFf4u83IuTxYs4UJqps4291_FKWF5euP8VXC3JqVVfVj6rUrro_xtLMeUuJ5kCFbtXKa7482YBCq6Nbgel_oZGXYgs9bLc2Wjns-aSNaRUmnjP3wQpiJZ_8jLuYEHQZCcOPrVPwxb06hMXNYCA4s8ZNRM9dUQMS7cFVFEWepeoCbdBQk8v84yt),
which yesterday was signed into law by Governor Gavin Newson. This new law
will explicitly permit the retail sale of products containing hemp-derived
extracts and cannabinoids, such as CBD. 

“As a California-based company, we are very pleased with the enactment of AB
45, which we believe will lead to significant retail expansion of CV
Sciences’ PlusCBD™ products in our home state, while also serving as a
model for responsible CBD legalization for other states,” said Joseph
Dowling, Chief Executive Officer of CV Sciences. “AB 45 will provide
Californians with access to the health and wellness benefits of our safe and
effective hemp-derived CBD. We look forward to working with our retail
partners to rapidly expand our distribution footprint in California.”

About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a
consumer product division focused on manufacturing, marketing, and selling
plant-based dietary supplements and CBD products to a range of market sectors;
and a drug development division focused on developing and commercializing
CBD-based novel therapeutics. The Company’s PlusCBD™ products are sold at
more than 7,300 retail locations throughout the U.S. and it is the top-selling
brand of hemp-derived CBD in the natural products market, according to SPINS,
the leading provider of syndicated data and insights for the natural, organic
and specialty products industry. CV Sciences follows all guidelines for Good
Manufacturing Practices (GMP) and the Company’s products are processed,
produced, and tested throughout the manufacturing process to confirm strict
compliance with company standards and specifications. With a commitment to
science, PlusCBD™ product benefits in healthy people are supported by human
clinical research data, in addition to three published clinical case studies
available on PubMed.gov. PlusCBD™ was the first hemp CBD supplement brand to
invest in the scientific evidence necessary to receive self-affirmed Generally
Recognized as Safe (GRAS) status. CV Sciences, Inc. has primary offices and
facilities in San Diego, California. Additional information is available from
OTCMarkets.com or by visiting www.cvsciences.com.

Additional information is available from OTCMarkets.com or by visiting
www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and
information, as defined within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is
subject to the Safe Harbor created by those sections. This material contains
statements about expected future events and/or financial results that are
forward-looking in nature and subject to risks and uncertainties. Such
forward-looking statements by definition involve risks, uncertainties.

Media Contact
ICR
Cory Ziskind
646-277-1232
cory.ziskind@icrinc.com 

Investor Contact
ICR
Reed Anderson
646-277-1260
 CVSciences@icrinc.com



(https://www.globenewswire.com/NewsRoom/AttachmentNg/b6d24907-4648-4d59-b927-204cc32d3b67)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.